Abstract: Nitric oxide donor compounds of the formula: are provided. In the formula, R is (CH2)n, wherein n ranges from 1 to 8 and wherein each hydrogen atom on the alkylene group and on the phenyl groups can optionally be replaced by a substituent selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, and hydroxy groups. A particularly preferred compound is 1,3-(nitrooxymethyl)phenyl 2-hydroxybenzoate. The compounds are useful for treating and preventing various conditions, including coronary artery disease.

Abstract: Nitric oxide donor compounds of the formula: 1

Abstract: Certain substances are provided which have the ability to relax smooth vascular muscle, having an endothelial lining, when administered in vitro or by intravenous injection. Examples of useful substances which are pharmaceutically-acceptable include phospholipase A.sub.2 (PLA.sub.2) and certain lysolecithins. The concentration required is at least about 3 units of PLA.sub.2 and at least about 10.sup.-5 Molar lysolecithin. The lysolecithins are dissolved in a suitable solvent, such as dimethyl sulfoxide, for injection. Alternatively, phospholipase A.sub.2 is administered directly. The resulting solutions should have a pharmacologically-effective amount of the substance dissolved therein. Importantly, the body does not develop a tolerance to the lysolecithin.